OIS@AAO
Ocata Therapeutics, which has trademarked the term Regenerative Ophthalmology, is developing stem cell therapies for Stargardt macular degeneration, dry age-related macular degeneration (AMD), and myopic…
Read MoreParticipant: Megan Baldwin Dr. Megan Baldwin is CEO/Managing Director of Circadian Technologies (Opthea) and has over 19 years of experience in preclinical and clinical development…
Read MoreParticipant: William L. Greene, MD Dr. Greene has served as CEO of Iconic Therapeutics since 2014. He brings 20 years of experience as an operating…
Read MoreAmblyotech CEO Joseph Koziak describes the company as a “hybrid” life science and software company that is refining its tablet-based treatment platform for amblyopia in…
Read MoreDigiSight Technologies announced at OIS@AAO 2015 that it was launching its Paxos product suite that combines its mobile vision assessment tool, ophthalmic imaging system and…
Read MoreMDbackline has developed a cloud-based, secure, online software that automates physician contact with patients outside of the office and can work with any electronic health…
Read MoreRhopressa is a Rho-kinase inhibitor that increases the outflow of the trabecular meshwork by relaxing it. It’s also a norepinephrine transport inhibitor that decreases the…
Read MoreFovista is an anti-platelet derived growth factor (PDGF) agent for wet age-related macular degeneration (AMD) combination therapy currently in phase 3 studies. Pending regulatory approval,…
Read MoreSpark was founded about 2 years ago with the vision of building a fully integrated gene therapy company with research and development, manufacturing, and commercial…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")